Topoisomerase 2β mutation impairs early B-cell development

Blood. 2020 Apr 23;135(17):1497-1501. doi: 10.1182/blood.2019003299.

Olivier Papapietro^{1

2}, Anita Chandra^{1

3}, Davide Eletto¹, Sarah Inglott⁴, Vincent Plagnol⁵, James Curtis¹, Mailis Maes¹, Ali Alisaac^{1

6}, Adriana S Albuquerque⁷, Eugenie Basseres², Olivier Hermine^{8

9}, Capucine Picard^{9

10

11}, Alain Fischer^{8

9

11

12}, Anne Durandy^{8

13}, Sven Kracker^{8

13}, Siobhan O Burns^{7

14}, Delphine Cuchet-Lourenco¹, Klaus Okkenhaug³, Sergey Nejentsev^{1

2}

¹ Department of Medicine, University of Cambridge, Cambridge, United Kingdom.
² Department of Molecular Cell Biology and Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
³ Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, United Kingdom.
⁴ Great Ormond Street Hospital National Health Service Trust, London, United Kingdom.
⁵ University College London Genetics Institute, London, United Kingdom.
⁶ College of Applied Sciences, Al Baha University, Al Baha, Saudi Arabia.
⁷ University College London Institute of Immunity and Transplantation, London, United Kingdom.
⁸ Imagine Institute, University Paris Descartes Sorbonne Paris Cité, Paris, France.
⁹ INSERM UMR 1163, Paris, France.
¹⁰ Study Center for Primary Immunodeficiencies, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris, France.
¹¹ Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
¹² Collège de France, Paris, France.
¹³ Human Lymphohaematopoiesis Laboratory, INSERM UMR 1163, Paris, France; and.
¹⁴ Department of Immunology, Royal Free London NHS Foundation Trust, London, United Kingdom.

No abstract available

Publication types